Journal
ADIPOCYTE
Volume 10, Issue 1, Pages 160-173Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/21623945.2021.1906510
Keywords
Obesity; insulin resistance; oxidative stress; inflammation; swertiamarin
Categories
Funding
- National Natural Science Foundation of China [81900778]
- Innovation Team in Zhejiang Province Universities
- Wenzhou Municipal Science and Technology Bureau [Y20190049]
Ask authors/readers for more resources
The study showed that supplementation with swertiamarin can attenuate weight gain and hepatic steatosis, improve glucose intolerance, oxidative stress, and insulin resistance, enhance insulin signaling, increase lipolysis, reduce adipocyte hypertrophy and macrophage infiltration, and alleviate obesity-associated inflammation by suppressing activation of the p38 MAPK and NF-kappa B pathways in obese mice fed with a high-fat diet.
Obesity is characterized by low-grade chronic inflammation, which underlies insulin resistance and non-alcoholic fatty liver disease (NAFLD). Swertiamarin is a secoiridoid glycoside that has been reported to ameliorate diabetes and NAFLD in animal models. However, the effects of swertiamarin on obesity-related inflammation and insulin resistance have not been fully elucidated. Thus, this study investigated the effects of swertiamarin on inflammation and insulin resistance in high-fat diet (HFD)-induced obese mice. C57BL/6 mice were fed a HFD or HFD containing swertiamarin for 8 weeks. Obesity-induced insulin resistance and inflammation were assessed in the epididymal white adipose tissue (eWAT) and livers of the mice. Swertiamarin attenuated HFD-induced weight gain, glucose intolerance, oxidative stress, and insulin resistance, and enhanced insulin signalling in mice. Compared to HFD-fed mice, the swertiamarin-treated mice exhibited increased lipolysis and reduced adipocyte hypertrophy and macrophage infiltration in eWAT. Moreover, swertiamarin alleviated HFD-mediated hepatic steatosis and inflammation by suppressing activation of the p38 MAPK and NF-kappa B pathways within the eWAT and liver of obese mice. In conclusion, supplementation with swertiamarin attenuated weight gain and hepatic steatosis, and alleviated obesity-associated inflammation and insulin resistance, in obese mice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available